Interestingly, patients who completed therapy showed significantly higher baseline serum THBS1 levels than patients who discontinued treatment (median 9163 vs. 4299 ng/mL), suggesting an association with tumor susceptibility to antiangiogenic therapy. The gene discussed is THBS1; the disease is neoplasm.